FDA approves gene therapy skin grafts for epidermolysis bullosa
2 Articles
2 Articles
First DEB patient dosed in trial of KB803 gene therapy eye drops
The first person has been dosed in a Phase 3 trial testing KB803, Krystal Biotech’s experimental eye drop formulation of the gene therapy beremagene geperpavec (B-VEC), for the treatment of eye problems in people with dystrophic epidermolysis bullosa (DEB). Krystal already markets a topical gel formulation of B-VEC for treating DEB-related skin wounds in the U.S. and Europe under the brand name Vyjuvek. To date, the new eye drop formula has been…
FDA approves gene therapy skin grafts for epidermolysis bullosa
A Stanford-led phase 3 trial shows gene therapy skin grafts significantly heal chronic wounds in patients with severe epidermolysis bullosa, reducing pain and improving quality of life Epidermolysis bullosa is the name for a group of rare inherited skin disorders that cause the skin to become very fragile; even the slightest touch can cause blistering. The condition is usually diagnosed in babies and young children, as symptoms can be evident fr…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium